Redx Pharma Management
Management criteria checks 3/4
Redx Pharma's CEO is Lisa Mary Anson, appointed in Jun 2018, has a tenure of 5.92 years. total yearly compensation is £608.13K, comprised of 94.9% salary and 5.1% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth £112.75K. The average tenure of the management team and the board of directors is 3 years and 3 years respectively.
Key information
Lisa Mary Anson
Chief executive officer
UK£608.1k
Total compensation
| CEO salary percentage | 94.9% |
| CEO tenure | 5.9yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3yrs |
| Board average tenure | 3yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | UK£608k | UK£577k | -UK£33m |
| Jun 30 2023 | n/a | n/a | -UK£31m |
| Mar 31 2023 | n/a | n/a | -UK£29m |
| Dec 31 2022 | n/a | n/a | -UK£24m |
| Sep 30 2022 | UK£637k | UK£606k | -UK£18m |
| Jun 30 2022 | n/a | n/a | -UK£18m |
| Mar 31 2022 | n/a | n/a | -UK£19m |
| Dec 31 2021 | n/a | n/a | -UK£20m |
| Sep 30 2021 | UK£2m | UK£615k | -UK£22m |
| Jun 30 2021 | n/a | n/a | -UK£20m |
| Mar 31 2021 | n/a | n/a | -UK£18m |
| Dec 31 2020 | n/a | n/a | -UK£14m |
| Sep 30 2020 | UK£619k | UK£481k | -UK£9m |
| Jun 30 2020 | n/a | n/a | -UK£8m |
| Mar 31 2020 | n/a | n/a | -UK£6m |
| Dec 31 2019 | n/a | n/a | -UK£5m |
| Sep 30 2019 | UK£439k | UK£390k | -UK£4m |
| Jun 30 2019 | n/a | n/a | -UK£5m |
| Mar 31 2019 | n/a | n/a | -UK£7m |
| Dec 31 2018 | n/a | n/a | -UK£8m |
| Sep 30 2018 | UK£372k | UK£100k | -UK£9m |
Compensation vs Market: Lisa Mary's total compensation ($USD759.28K) is above average for companies of similar size in the UK market ($USD344.28K).
Compensation vs Earnings: Lisa Mary's compensation has been consistent with company performance over the past year.
CEO
Lisa Mary Anson (55 yo)
5.9yrs
Tenure
UK£608,127
Compensation
Mrs. Lisa Mary Whewell Anson serves as the Chief Executive Officer and Executive Director at Redx Pharma PLC since June 1, 2018. She has been President of AstraZeneca UK since 2012 and brings significant l...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 5.9yrs | UK£608.13k | 0.19% £ 112.8k | |
| Chief Financial Officer | 3yrs | no data | no data | |
| Chief Operating Officer | 3yrs | UK£210.91k | no data | |
| Chief Scientific Officer | 10.3yrs | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| General Counsel & Company Secretary | 2.3yrs | no data | no data | |
| Head of Communications | 2.1yrs | no data | no data | |
| Senior Vice President of Chemistry | 8.3yrs | no data | no data | |
| Senior Vice President of Biology | no data | no data | no data | |
| Head of Development Operations | no data | no data | no data | |
| Head of Nonclinical Development | 3.3yrs | no data | no data | |
| Interim Chief Medical Officer | less than a year | no data | no data |
3.0yrs
Average Tenure
55yo
Average Age
Experienced Management: REDX's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 5.9yrs | UK£608.13k | 0.19% £ 112.8k | |
| Independent Non-Executive Director | 6.5yrs | UK£48.75k | 0.038% £ 21.9k | |
| Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 8.3yrs | UK£49.00k | no data | |
| Independent Non-Executive Chair | 2.4yrs | UK£85.00k | 0.022% £ 12.7k | |
| Independent Non-Executive Director | 2.3yrs | UK£41.50k | no data | |
| Shareholder Representative Non-Executive Director | 3yrs | no data | no data |
3.0yrs
Average Tenure
65yo
Average Age
Experienced Board: REDX's board of directors are considered experienced (3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/01 12:49 |
| End of Day Share Price | 2024/05/01 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Redx Pharma Plc is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian White | Cantor Fitzgerald Europe |
| Martin Hall | Hardman & Co. |
| Michael Mitchell | Panmure Liberum Historic (Panmure Gordon) |